MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update
CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update. “We continue to make significant progress with advancing the clinical development of THIO. We recently dosed the first patient … [Read more…]
